Lennham Pharmaceuticals, Inc.

CONCORD, MA · Founded 2019 · CIK 0001853301 · Biotech · Private

Deuterium-substituted pharmaceutical compounds

lennham.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$3.5M
2 Form D · Apr 2023
42 months since last filing
Contracts
—
No federal contracts on record
Patents
40
12 granted · 28 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$2,325,000
Private capital raisedForm D · SEC$1,200,000
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2319INMUNE BIO, INC.—$8.0M
2320ARUKA BIO, INC.—$3.6M
2321Genomics PLC——
2322Lennham Pharmaceuticals, Inc.—$3.5M
2323SUS CLINICALS INC—$3.5M
2324Myricx Bio——
2325Abiologics——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 3 related persons
  • Benjamin EnersonExecutive Officer
  • Corey MacGregorExecutive Officer
  • Bradford SippyDirector · Executive Officer

Patents

USPTO · 12 granted of 40

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.